Evaluating the Response and Safety of Inactivated COVID-19 Vaccines in Liver Transplant Recipients

Figures & data

Figure 1 Flow chart of the evaluation.

Table 1 Baseline Characteristics of LTx Recipients and Comparison According to Serological Response

Characteristics	Entire (n=35)	Seronegative (n=29)	Seropositive (n=6)	P value	Missing
Age, years	47 (40–53)	47 (41–53)	47 (31–55)	0.685	0
Male sex	30 (85.7)	26 (89.6)	4 (66.7)	0.143	0
BMI, kg/m^2	23.8 (20.8–25.6)	23.9 (21.9–25.7)	20.4 (18.9–24.4)	0.124	0
Time since LT	2.4 (2.0–5.5)	2.3 (1.9–4.0)	6.3 (2.3–8.6)	0.025	0
IL-2R Induction	31 (88.5%)	28 (96.5%)	3 (50%)	0.011	0
Immunosuppressant				0.897	0
Tacrolimus	28	23	5		0
Cyclosporin	1	1	0		0
Sirolimus	6	5	1		0
MPA	15 (42.8%)	15 (52.7%)	0 (0%)	0.027	0

Abbreviations: LTx, liver transplant; BMI, body mass index; IL-2R, interleukin-2 receptor; MPA, derivatives from mycophenolic acid.

Table 2 The Side Effects and Blood Tests After Vaccination

Characteristics	Entire (n=35)	Seronegative (n=29)	Seropositive (n=6)	P value	Missing
Side effects	4	2	2		0
Dizziness with poor appetite	2	1	1
Fatigue	1	0	1
Chest distress	1	1	0
Total bilirubin	14.0 (8.9–19.5)	14.0 (9.8–19.0)	15.2 (6.4–25.6)	0.933	3
Serum creatinine	82 (66–94)	83 (67–100)	75 (63–87)	0.334	3
eGFR	94 (75–105)	94 (72–105)	90 (85–118)	0.438	4
WBC	5.1 (4.1–6.0)	5.1 (4.2–5.8)	5.3 (2.8–6.6)	0.638	3

Abbreviations: eGFR, estimated glomerular filtration rate; WBC, white blood cell.